18.50
0.05%
-0.01
After Hours:
18.50
Myriad Genetics, Inc. stock is currently priced at $18.50, with a 24-hour trading volume of 476.27K.
It has seen a -0.05% decreased in the last 24 hours and a -14.35% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $18.54 pivot point. If it approaches the $18.18 support level, significant changes may occur.
Myriad Genetics, Inc. Stock (MYGN) Financials Data
Myriad Genetics, Inc. (MYGN) Revenue 2024
MYGN reported a revenue (TTM) of $753.20 million for the quarter ending December 31, 2023, a +11.03% rise year-over-year.
Myriad Genetics, Inc. (MYGN) Net Income 2024
MYGN net income (TTM) was -$263.30 million for the quarter ending December 31, 2023, a -135.09% decrease year-over-year.
Myriad Genetics, Inc. (MYGN) Cash Flow 2024
MYGN recorded a free cash flow (TTM) of -$184.20 million for the quarter ending December 31, 2023, a -21.50% decrease year-over-year.
Myriad Genetics, Inc. (MYGN) Earnings per Share 2024
MYGN earnings per share (TTM) was -$3.20 for the quarter ending December 31, 2023, a -130.22% decline year-over-year.
Myriad Genetics, Inc. Stock (MYGN) Latest News
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
GlobeNewswire Inc.
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Zacks Investment Research
Myriad Genetics (MYGN) Announces Favorable Research Results
Zacks Investment Research
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Zacks Investment Research
Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research
Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?
Zacks Investment Research
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Cap:
|
Volume (24h):